Upcoming Event: FGH Academy of Competitive Intelligence Certification Program Boston June 12-16, 2017

Posted by Fuld + Company

May 24, 2017 3:15:13 PM

Join Leonard Fuld, Dr. Ben Gilad, Ken Sawka and Dr. Helen Rothberg in Boston, MA for their core and advanced certification courses. Competitive intelligence is not collecting random information. It's developing a skilled view of competitive risks and opportunities.

Advanced and Core courses offered in June 2017. Core courses offered in June and October 2017.
June registration
 June 12-16

October registration October 23-26

Read More

Topics: Competitive Intelligence, Events, FGH Academy of Competitive Intelligence, Fuld, Leonard

Strategies for Investing in Developing Markets

Posted by Robert Flynn

May 17, 2017 3:01:13 PM

The global economy is in transition, not so much as the result of fluctuating superpower politics, but more so as the quiet byproduct of shifting investment in emerging economies. We are at the end of supersized returns previously found in Brazil, Russia, India, China, and South Africa (BRICS), foreign direct investment constants since 2001 that have in recent years become increasingly fragile economies. Their era as primary centers for investment has been replaced by a “Frontier Era,” a period marked by a concentration on economies scattered throughout Africa and Asia. A dramatic shift as hundreds of millions of dollars in foreign direct investment will swing from the pockets of one group to new, emerging markets.  

Read More

Topics: New Market Entry, Competitive Strategy, risk management

The Importance of Brand Awareness in the Pharmaceutical Industry

Posted by Neha Suri

May 10, 2017 10:15:38 AM

Co-Written by Karl Varkey

Today’s reality for pharmaceutical companies is anything but care free. Competition from the generics market continues to rise, the FDA’s approvals of new drugs has declined, and resolution of the debate surrounding the Affordable Care Act is uncertain. Additionally, the new administration has called for pricing restraints. This is certainly enough to cause angst among the most experienced pharmaceutical executives.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Competitive Strategy

Competitive Chess with Cheese

Posted by Tess Fagan

Apr 25, 2017 10:25:27 AM

There’s a savage war going on at your local deli counter. Shelf space at America’s deli counters is the newest casualty of a cutthroat retail brand battle in today’s supermarkets. Deeply entrenched and beloved brands like Boar’s Head and Land O’Lakes are silently duking it out in a fight over who reigns supreme in the deli section. The result to the winner is likely to be increased revenue; for the shopper this is a race to the bottom, and we should anticipate less choice and increased prices.

Read More

Topics: Consumer Goods, Brand Insights, Market Analysis, Competitive Strategy

Quality Drug Data Not a Guarantee of Future Revenue

Posted by David Staknis

Apr 12, 2017 12:07:23 PM

On March 16, 2017, Amgen released positive cardiovascular outcomes data for its PCSK9 inhibitor, Repatha. Yet, it could be tough going to receive wide coverage of the drug from managed care companies due to concerns over high cost and availability of efficacious, economical alternatives. Positive outcomes data alone will not sway payers if the cost-benefit ratio is too high, especially when established and more cost-effective options are available and acceptable.

Read More

Topics: Product Positioning, Competitive Strategy, pharmaceutical

Restaurants are Using Digital Menus to Gain a Competitive Advantage

Posted by Ben Price

Apr 7, 2017 3:03:51 PM

The typical customer experience at restaurants is uninspiring. The order taker welcomes the patron. He or she may list off some specials then disappear, coming back only for transactional purposes like recording orders and dropping off food.

Read More

Topics: Competitive Intelligence, Travel/Hospitality, Competitive Strategy

Fake News and Competitive Strategy

Posted by Malini Solanki

Jan 3, 2017 1:54:02 PM

The diagnostic industry provides essential information for healthcare, and is driven by medical technology, the aging population, and the complexity of disease. One sector, the global blood testing market, in 2015 was valued at $51.5 billion and is expected to grow to $62.9 billion by 2024. Understanding how to craft strategy in this market is critical, given the funding required for new ventures, and it is nuanced, given the often unusual business practices that can be employed by one's competitors. 

Read More

Topics: Competitive Intelligence, Pharma, Competitive Strategy

New Year's Resolutions for the Competitive Strategist

Posted by Ken Sawka

Dec 19, 2016 10:38:10 AM

As 2016 ends, few would argue that most businesses are in for a roller coaster ride in 2017.  The United States is set for a hard-right turn politically, the Brexit process is facing new uncertainties regarding its duration and manner, and accusations of Russian cyber espionage and China’s muscle-flexing in the Asia Pacific region foreshadow turbulence in international relations. Longer-term demographic shifts in developed and developing economies will continue to affect wealth patterns and create new consumption opportunities.  What are strategists to do?

Read More

Topics: Competitive Intelligence, Competitive Strategy, Early Warning

The Ever Shifting Pharmaceutical Marketplace – Biosimilars and Interchangeability

Posted by Varun Naik

Dec 12, 2016 10:22:27 AM

The FDA recently approved Amjevita (adalimumab-atto), Amgen’s adalimumab biosimilar product for seven inflammatory indications in adult patients1. It was the fourth biosimilar approved by the FDA, and was announced just days after approval was granted for Sandoz’s Erelzi (etanercept-szzs), an Enbrel® biosimilar. Both Enbrel® and Humira® are blockbuster drugs with worldwide revenues over $8.7 and $14 billion respectively and the introduction of related biosimilars will certainly impact their growth potential by providing patients with new and different options and greater access to treatments. Further, biosimilars are expected to generate considerable cost savings for patients and reduce the burden on healthcare expenses.

Read More

Strategies for Surviving an Industry Downturn

Posted by Nathaniel Emmons

Dec 7, 2016 11:12:13 AM

Co-written by Diane Borska

In late October, GE announced that it is spinning off its oil and gas business and merging it with Baker Hughes, embarking on a strategy of convergence, expanding its offerings and therefore the potential revenue it can generate, to remain vibrant and viable in the current industry downturn. In 2014, GE Oil and Gas developed a business plan based on oil prices of approximately $100 per barrel, but by January 2016, oil prices plummeted to $27 a barrel, resulting in a 30% drop in profitability. Developing strategies for how to respond to downturn is critical.

Read More

Topics: Competitive Intelligence, Innovation, Industry Convergence, Competitive Strategy

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.